Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to optimize current treatment of genotype 2 hepatitis C virus infection.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2014

Marciano Sebastián, Gadano Adrián C

Abstract excerpt

The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG-IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight-based RBV dosing approach has been considered satisfactory in patients with positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 24373073
DOI: 10.1111/liv.12399

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to optimize current treatment of genotype 2 hepatitis C virus infection.PMID 24373073Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

Optimal therapy of genotype-2 chronic hepatitis C: what's new?Semantic proximity Read ↗

What's new in HCV genotype 2 treatment.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 4 patients.Semantic proximity Read ↗

How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.Semantic proximity Read ↗

Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.Semantic proximity Read ↗

[Treatment of HCV genotype 2 infection].Semantic proximity Read ↗

[Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.Semantic proximity Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.